Update shared on 23 Nov 2025
Analysts have maintained their price target for Kiniksa Pharmaceuticals International at $54.00 per share. Ongoing research highlights the company's stable valuation, with promising momentum from new product launches and anticipated improvements in earnings.
Analyst Commentary
Bullish Takeaways- Bullish analysts note that Kiniksa is at a pivotal stage with the ongoing launch of Arcalyst, which is expected to drive near-term growth and momentum.
- The potential of KPL-387 to offer more favorable dosing could extend Kiniksa's therapeutic franchise and contribute to the company’s competitive position in the market.
- Anticipated earnings improvements are cited as a key factor supporting the current valuation and price targets set by analysts.
- Overall, the firm’s stable valuation appears supported by successful product rollouts and the constructive outlook for continued revenue expansion.
- Bearish analysts warn that reliance on successful execution of new product launches introduces risk to earnings momentum and projected growth.
- There is caution regarding the competitive landscape, as emerging therapies could impact long-term differentiation and market share.
- Concerns remain around regulatory and commercialization hurdles that could affect both the near-term and sustained outlook.
What's in the News
- Kiniksa Pharmaceuticals International raised net sales guidance for full year 2025, now expecting between $670 million and $675 million. This represents a $40 million increase at the midpoint (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $54.00 per share, reflecting steady expectations for Kiniksa's future value.
- The discount rate has risen slightly, from 7.36% to 7.39%. This may signal a modest increase in perceived risk or required return.
- Revenue growth projections are unchanged at 23.7%, indicating consistent expectations for top-line expansion.
- Net profit margin is virtually the same, holding at approximately 15.1%.
- The future P/E ratio has fallen marginally, moving from 34.03x to 33.66x. This suggests minor improvement in earnings expectations relative to price.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.